8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2008

Shire Limited

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0484822

(Commission File Number)                (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.  Other Events

     Shire Limited has issued the press releases attached hereto as Exhibits 99.01, 99.02 and 99.03 which are incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibits are filed herewith:

99.01              Press Release dated August 4, 2008

99.02              Press Release dated August 4, 2008

99.03              Press Release dated August 4, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE LIMITED
By:	/s/ A C Russell
	Name:   Angus Russell
	Title:     Chief Executive Officer

Dated: August 4, 2008

EXHIBIT INDEX
Number	Description
99.01	Press Release dated August 4, 2008
99.02	Press Release dated August 4, 2008
99.03	Press Release dated August 4, 2008

EX-99.1

Exhibit 99.01

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of Acquisition of American Depository Shares by a Director/Person Discharging Managerial Responsibilities

Basingstoke, UK and Philadelphia, US – August 4, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on August 1, 2008 the trustee of the Shire Employee Benefit Trust informed the Company that, on August 1, 2008, 6,471 American Depositary Shares in the Company (“ADSs”) had been allocated under the Shire Executive Annual Incentive Plan (the "Plan") to Mr. Matthew Emmens.  The ADSs were bought on the same date at a price of US$50.9298 per ADS. The allocation is in respect of the share based element of Mr. Emmens’ 2008 pro-rated bonus which was based on his 2008 performance whilst Chief Executive Officer of the Company.

Under the terms of the Plan the ADSs will not normally be released to participants for three years.

The bonus was paid under Mr. Emmens’ contract as Chief Executive Officer and represents his final bonus as Chief Executive Officer prior to him becoming Chairman on June 18, 2008.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

EX-99.2

Exhibit 99.02

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Director/PDMR Shareholding

Basingstoke, UK and Philadelphia, US – August 4, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on August 1, 2008, Mr Graham Hetherington was granted the following awards under the Shire Portfolio Share Plan (the "Plan"), following his appointment on July 1, 2008 as the Company’s Chief Financial Officer.

Awards of Stock Settled Appreciation Rights ("SARs") under Part A of the Plan

Type of Security	No. of Ordinary Shares	Exercise Price
Ordinary Share	100,000	£8.675

SARs will normally vest after three years, subject to performance targets being satisfied. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.

Performance Share Awards ("PSAs") under Part B of the Plan

Type of Security	No. of Ordinary Shares	Market value
Ordinary Share	75,000	£8.675

The PSAs will normally vest after three years, subject to performance targets being satisfied. Once vested, sufficient ordinary shares will be transferred or allotted to the participant within 30 days.  No consideration was paid for the grant of PSAs.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

EX-99.3

Exhibit 99.03

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of Acquisition of American Depository Shares by a Director/Person Discharging Managerial Responsibilities

Basingstoke, UK and Philadelphia, US – August 4, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on August 1, 2008 it was notified by Dr. Michael Rosenblatt, a Non-Executive Director of the Company, of an acquisition on the same day of 385 American Depository Shares, representing 1,155 ordinary shares of £0.05 each. The American Depository Shares were acquired at a price of US$52.2765 per American Depository Share.

Following this transaction, Dr. Rosenblatt holds 385 American Depository Shares in the Company.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street , St Helier, Jersey JE4 8PX